Activities Report March 2026 and Appendix 4C
Filed with ASX · · 24 pages · English
Summary by 6ix AI
The report highlights a revenue growth compared to the previous quarter and the same quarter last year, indicating positive business momentum. Additionally, the company has secured several distribution agreements and is expanding its operations into new markets, including a planned Centre of Excellence in Hong Kong. The filing also includes a cash flow report, showing the company's financial position and cash usage during the quarter.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Osteopore
- Further Drawdown of T2 of the Redeemable Convertible Notes
- Clarification - agreement for injectable regen bone filler
- OSX signs agreement for injectable regenerative bone filler
- OSX secures distribution for autologous dentin bone graft
- Appendix 4E Preliminary Final Report
Later from Osteopore
- OSX secures Hainan FDA approval for orthopaedic devices
- Activities Report June 2026 and Appendix 4C
- OSX strikes orthopaedic deal for 5 Middle East countries
- Activities Report September 2026 and Appendix 4C
Follow Osteopore into a list and get an email when it puts out news.
Follow Osteopore